Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00962507 · ClinicalTrials.gov registry record · Phase 1
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00962507 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 11 participants.
The verdict
NCT00962507, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
RATIONALE: Panobinostat and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Giving panobinostat together with everolimus may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with everolimus in treating patients with relapsed or refractory lymphoma or multiple myeloma.
Interventions
- OTHER laboratory biomarker analysis
- DRUG panobinostat
- OTHER pharmacological study
- DRUG everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00962507
The ClinicalTrials.gov registry entry for NCT00962507 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00962507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00962507 about?
NCT00962507 is a clinical study titled "Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma". RATIONALE: Panobinostat and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Giving panobinostat together with everolimus may kill more cancer cells. PURPOSE: This phase I trial is studying the side effec...
What is the current status of trial NCT00962507?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2009-07. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00962507?
The interventions under investigation include: laboratory biomarker analysis (OTHER), panobinostat (DRUG), pharmacological study (OTHER), everolimus (DRUG).
Who is sponsoring clinical trial NCT00962507?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.